



## Investigational Cellular Therapy Services

\* The Cellular Therapy Services (CTS) at Mount Sinai Hospital (MSH) supports investigators in the conduct of human clinical trials utilizing cell-based investigational products. These clinical trials may be industry or federally sponsored, investigator initiated trials (IIT), and compassionate use/expanded access drugs. CTS ensures efficient management of investigational products (IP) adhering to protocol, institutional, local, and federal guidelines and regulations (FDA, NYDOH and FACT) and support the clinical research teams on all aspects related to handling of cellular products from receipt and storage to preparation for infusion into patients.

\* The following services are components of Cellular Therapy Services (CTS):

- **Clinical Cellular Therapy Service/BMT Program:** <https://www.mountsinai.org/care/cancer/treatments/cellular-therapy>
- **Clinical BMT Program:** <https://www.mountsinai.org/care/cancer/services/blood/bone-marrow-transplant>
- **Apheresis Service:** <https://icahn.mssm.edu/about/departments/pathology/clinical/transfusion-cellular>
- **Cellular Therapy Laboratory (CTL):** <https://icahn.mssm.edu/about/departments/pathology/clinical/transfusion-cellular>

If Mount Sinai Hospital is being evaluated as potential site utilizing cell-based investigational products (IP), CTS must be consulted, included in the evaluation, approval and study onboarding processes. Use the guide below to determine the need and the degree of involvement for each CTS component.

